Evolución de mujeres con osteoporosis tratadas durante más de tres años

Revista Espa?ola de Enfermedades Metabólicas óseas Pub Date : 2009-07-01 DOI:10.1016/S1132-8460(09)73228-3

J.A. Olmo Fernández-Delgado , M. Canteras Jordana

{"title":"Evolución de mujeres con osteoporosis tratadas durante más de tres años","authors":"J.A. Olmo Fernández-Delgado , M. Canteras Jordana","doi":"10.1016/S1132-8460(09)73228-3","DOIUrl":null,"url":null,"abstract":"<div><p>We are going to show the progress of 41 postmenopausal patients who have followed treatment for more than three years (86 months). Assessing several factors such as: development of the bone mineral density (BMD), adherence to therapeutic treatment, incidence of fractures and risk factors. Thirty five patients (85%) showed increases of the BMD in the spine with an average increase of 21%, and presented statistic changes (p<0.005); 63% presented statistic changes in the hip but with not significant increases. Thirteen patients showed some fracture through fragility and 6 of them suffered more than one episode. By order of frequency: vertebral (spinal) fractures 8 (19.5%), radius 5 (12%), epiphysis of humerus 3 (7, 5%) and hip 2 (5%).</p><p>The most used treatment was alendronate (71%), followed by raloxifene (58%) and risedronate (54%). Using the Morisky test, the 48% of the patients were reliable.</p><p>We have found correlation between increases of the BMD and risk of fracture, not being found related to other risk factors.</p></div>","PeriodicalId":101109,"journal":{"name":"Revista Espa?ola de Enfermedades Metabólicas óseas","volume":"18 3","pages":"Pages 45-50"},"PeriodicalIF":0.0000,"publicationDate":"2009-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1132-8460(09)73228-3","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista Espa?ola de Enfermedades Metabólicas óseas","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1132846009732283","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 1

Abstract

We are going to show the progress of 41 postmenopausal patients who have followed treatment for more than three years (86 months). Assessing several factors such as: development of the bone mineral density (BMD), adherence to therapeutic treatment, incidence of fractures and risk factors. Thirty five patients (85%) showed increases of the BMD in the spine with an average increase of 21%, and presented statistic changes (p < 0.005); 63% presented statistic changes in the hip but with not significant increases. Thirteen patients showed some fracture through fragility and 6 of them suffered more than one episode. By order of frequency: vertebral (spinal) fractures 8 (19.5%), radius 5 (12%), epiphysis of humerus 3 (7, 5%) and hip 2 (5%).

The most used treatment was alendronate (71%), followed by raloxifene (58%) and risedronate (54%). Using the Morisky test, the 48% of the patients were reliable.

We have found correlation between increases of the BMD and risk of fracture, not being found related to other risk factors.

查看原文本刊更多论文

治疗3年以上女性骨质疏松症的演变

我们将展示41名绝经后患者的治疗进展，这些患者已接受治疗超过3年(86个月)。评估几个因素，如:骨密度(BMD)的发展，治疗依从性，骨折发生率和危险因素。35例(85%)患者脊柱骨密度升高，平均升高21%，有统计学变化(p <0.005);63%的患者髋部有统计学变化，但无明显增高。13例患者出现脆性骨折，其中6例发生一次以上骨折。按发生频率排序:椎体(脊柱)骨折8例(19.5%)，桡骨骨折5例(12%)，肱骨骨骺骨折3例(7.5%)，髋关节骨折2例(5%)。使用最多的是阿仑膦酸钠(71%)，其次是雷洛昔芬(58%)和利塞膦酸钠(54%)。使用莫里斯基测试，48%的患者是可靠的。我们发现骨密度的增加与骨折风险之间存在相关性，而没有发现与其他危险因素相关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Revista Espa?ola de Enfermedades Metabólicas óseas

自引率

0.00%

发文量